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Abstract Purpose: The main objectives of this study
were to identify risk factors for local in-breast tumor
recurrence after breast-conservation and to evaluate the
impact of IBTR (in-breast tumor recurrence) on overall
survival. Methods: A total of 335 consecutive patients with
346 invasive and in situ breast cancers were treated with
breast conserving therapy. Univariate and multivariate
statistical analysis were performed and survival rates were
calculated and analyzed using the Kaplan–Meier method.
Results: With a median follow-up period of 70.6 months 14
patients (4%) developed an IBTR. Overall survival and the
disease-free 8-year actuarial survival of patients were 95%
and 93%, respectively. The overall survival of patients with
tumour recurrence on any site was significantly shorter
than of those without recurrence (64% versus 85% after
8 years of follow-up; P \ 0.0001). Similarly, overall sur-
vival was significantly reduced in patients with distant
metastases compared to all others without distant disease
(88% versus 40% after 8 years; P \ 0.0001). In contrast,
overall survival of patients who experienced IBTR did not
differ significantly from the group of patients who never
developed IBTR (87% versus 70% after 8 years of follow-
up). By univariate analysis, lobular carcinoma, high grade
tumours, multifocality, concomitant LCIS and DCIS, the
absence of estrogene and progesterone receptor status, as
well as R1-status, were significant predictors of IBTR. By
multivariate analysis, only R1-status (P \ 0.002) and the
presence of LCIS around the invasive tumour (P \ 0.03)
remained as significant factors predicting IBTR. Conclu-
sions: Concomitant lobular carcinomas in situ, as well as
R1 surgical status are independent significant risk factors
for in breast tumor recurrence after breast conserving
therapy.
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Introduction
Surgical therapy for breast cancer has significantly devel-
oped over the past three decades. During the 1970s, Fisher in
New York and Veronesi in Milano, Italy, revolutionized the
surgical treatment with the paradigm shift from the standard
modified radical mastectomy towards breast conservation
(i.e. lumpectomy and adjuvant radiotherapy). The results of
two large randomized controlled series have firmly estab-
lished the principle of breast conservation being equally safe
and effective as mastectomy for the majority of patients with
stage I and II disease [1, 2], while achieving cosmetically
superior results. Moreover, 20 and 25-year follow-up series
for breast conserving therapy have further confirmed that,
compared to mastectomy, breast conserving therapy (BCT)
achieved an identical survival rate [3, 4].
During breast conservation (also known as lumpectomy,
segmental mastectomy or wide local excision), the tumor is
removed with a disease free margin. Although the minimal
size of tumor free resection margin is not definitively
identified, there is compelling evidence that positive
resection margins lead to an increased rate of local in-
breast recurrence [5–7].
Two etiologic types of ipsilateral, so-called in-breast
tumor recurrence (IBTR) exist:(i) True local recurrences
develop from cancer cells that have not been completely
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removed during surgery; (ii) new primary tumors are
defined as new cancers arising from the residual ipsilateral
breast parenchyma [8].
Adjuvant percutaneous radiation therapy significantly
reduces the rate of local recurrences, and data from this
overview published in 2002 indicate that the addition of
radiation therapy also improves overall survival [9].
While radiotherapy clearly reduces the rate of IBTR, the
following factors have been attributed to increase the risk of
IBTR: Young age at the time of primary therapy [10, 11],
high tumor grade [12–15], specific histological types, for
example concomitant LCIS [16], lympho-vascular invasion
[10, 12–15, 17], extensive intraductal component (EIC) [10,
13, 14, 17–20] and the lack of adjuvant systemic therapy
like hormone- and chemotherapy [1, 21]. Concerning EIC,
two main studies have demonstrated, that providing clear
margins, there is no increased rate of local recurrence in
patients with EIC [5, 6].
The objective of our study was to analyze a prospec-
tively maintained database for factors influencing
postoperative IBTR and survival.
Materials and methods
Between January 1990 and December 2004, 335 patients
with 346 invasive and in situ breast cancers were treated
with breast conserving therapy at the Department of Sur-
gery, University Hospital Basel. All patient’s data have
prospectively been entered into a computerized database.
Bilateral tumors were observed in 11 patients (3.3%). At
the time of diagnosis, the patients had a median age of
54.2 years (range 41.5–81.3 years).
The surgical procedure consisted of a quadrantectomy or
lumpectomy with axillary nodal staging for invasive can-
cers. Axillary lymph node dissection of level 1 and 2 was
performed during the first study period until 1998. In 1999,
sentinel lymph node procedure was introduced at the
University Hospital Basel [22]. After a validation period,
standard axillary lymph node dissection was only per-
formed if macrometastases were found in the excised
sentinel lymph node or when the sentinel lymph node could
not reliably be identified.
Adjuvant chemotherapy or hormonal therapy was per-
formed according to the newest St. Gallen consensus
available at the time of treatment [23]. Generally, patients
with advanced stage carcinomas were offered an adjuvant
chemotherapy, neoadjuvant chemotherapy or in selected
cases both of them.
The majority of patients (82.6%) underwent adjuvant
radiation therapy to the breast; 4 Patients (1.2%) were
treated in a neoadjuvant setting by breast irradiation; 54
patients did not receive radiation; this either because of
denial from the patient or histological subtypes. Radiation
therapy was administered with a total dose of 50.4 Gy to
the whole breast (5 9 1.8 Gy weekly). Patients younger
than 60 years with R0 excision received an additional
boost dose of 10 Gy (5 9 2 Gy for one week) to the tumor
bed. Patients with close margins (\3 mm) received a boost
dose of 20 Gy (5 9 2 Gy weekly) to the tumor bed irre-
spective of age. Patients older than 60 years with R0
excision received no additional boost dose on contrary to
patients with close margins (\3 mm) excision who
received a boost dose of 20 Gy (5 9 2 Gy weekly). Boost
doses were only applied to the tumor bed. Radiation ther-
apy to the whole breast was administered using photons,
and to the tumor bed using electrons.
In order to classify also the tumors with skin infiltration
according to latest standards, the new TNM classification
was used [24].
This study has been approved by the regional Ethical
Committee responsible for the University Hospital Basel.
Statistical analysis was performed with the STATISTI-
CA software package (Statsoft Inc. Tulsa, Oklahoma,
U.S.A.). The Mann–Whitney-U test was used for univariate
analysis of continuous variables when comparing two
independent groups, and the chi-squared test for 2 9 2
categorical tables. Clinical and pathological factors that
have been tested significantly by univariate analysis
underwent multivariate analysis using the Cox regression
model. Survival curves were calculated according to the
Kaplan–Meier life-table method with differences in sur-
vival curves tested by the log-rank test. Patient’s
characteristics are listed and described in Table 1.
Results
Median follow-up was 70.6 months (range 7–190 months).
11 out of 346 patients (3.2%) suffered from distant
metastases and 14 (4.0%) had developed IBTR. The overall
survival and the disease-free 8-year actuarial survival of
patients were 95% and 93%, respectively (Fig. 1).
The overall survival of patients with tumour recurrence
on any site was significantly shorter than of those without
recurrence (64% versus 85% after 8 years of follow-up;
P \ 0.0001; Fig. 2). Similarly, overall survival was sig-
nificantly reduced in patients with distant metastases
compared to all other patients without distant disease (88%
versus 40% after 8 years; P \ 0.0001; Fig. 3). In contrast,
overall survival of patients who experienced IBTR did not
differ significantly from the group of patients who never
developed IBTR (87% versus 70% 8 years of follow-up),
as shown in Fig. 4.
By univariate analysis, lobular carcinoma, high grade
tumours, multifocality, concomitant LCIS and DCIS, the
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absence of estrogene and progesterone receptor status, as
well as R1-status, were significant predictors of IBTR. In
contrast, nodal status was not a predictive factor for IBTR
(Tables 2, 3).
By multivariate analysis, the R1-status (P \ 0.002) and
the presence of LCIS around the invasive tumour
(P \ 0.03) remained as significant factors predicting IBTR
(Table 4).
The treatment of IBTR consisted of mastectomies (9 out
of 14) or yet another breast conservation (4 out of 14). Due
to denial of therapy, one patient’s IBTR was not treated at
Table 1 Cases characteristics (N = 346)
Characteristics No. %
Age group (years)
Median age
20–40 24 6.9
40–60 161 46.5
60–80 149 43.1
[80 12 3.5
Staging
T1 210 60.7
T2 97 28.0
T3 1 0.3
T4 6 1.7
Tis 28 8.1
Unknown 4 1.2
Node status
N0 249 71.9
N1 71 20.5
N2 10 2.9
N3 3 0.9
NX 10 2.9
Unknown 3 0.9
M status
M0 331 95.7
M1 1 0.3
Mx 13 3.6
Unknown 1 0.4
Grading
G1 75 21.7
G2 151 43.6
G3 98 28.3
Unknown 22 6.4
Histopathological type
Invasive ductal 233 67.3
Invasive lobular 37 10.7
Tubular 19 5.5
Mucinous 10 2.9
Medullary 10 2.9
Invasive ductulolobular 8 2.3
Non invasive Adenoca 29 8.4
R-status (including peritumoral DCIS)
R0 320 92.5
R1 25 7.2
R2 1 0.3
Lymphovascular invasion
Yes 79 22.8
No 265 76.6
Unknown 2 0.6
Table 1 continued
Characteristics No. %
Extensive intraductal component
Yes 24 6.9
No 310 89.6
Unknown 12 3.5
Localisation
Left breast 181 52.3
Right breast 165 47.7
Axillary dissection
Yes 201 58.1
No 137 39.6
Unknown 8 2.3
ER status
Yes 264 76.3
No 54 15.6
Unknown 28 8.1
PR status
Yes 222 64.2
No 100 28.9
Unknown 24 6.9
Hormone therapy
Yes 240 69.4
No 87 25.1
Unknown 19 5.5
Chemotherapy
Neoadjuvant 3 0.9
Adjuvant 60 17.3
Neoadjuvant ? Adjuvant 2 0.6
No 280 80.9
Unknown 1 0.3
Radiotherapy
Neoadjuvant 4 1.2
Adjuvant 288 83.2
No 54 15.6
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all. In both groups, mastectomies and breast conservation,
one second recurrence has been reported. The pattern of all
recurrences is demonstrated in Table 5 and the course of
disease of patients with IBTR is shown in Table 6.
Discussion
Since Fisher [1] and Veronesi [2] have established the
equality in outcome of breast-conserving surgery followed
by radiation therapy compared to modified radical mastec-
tomy, BCT has become standard of care for early breast
cancer. The search for identification of relevant risk factors
for local tumor relapse (i.e. IBTR) has widely been made but
is still ongoing. The purpose of this study was to explore a
prospectively maintained database of 346 consecutive
patients with primary breast cancer undergoing BCT from
1990 to 2004 at the Department of Surgery, University
Hospital Basel, and to examine potential risk factors for
IBTR and their prognostic influence on patient’s overall
survival and also to compare them with published material.
In the current study we used an univariate and a mul-
tivariate analysis of the collected data material in order to
detect factors predicting for the occurrence of IBTR. We
found that several significant tumor characteristics were
predictive for IBTR including lobular carcinoma, high
tumor grade, R1-status, absence of estrogene and proges-
terone receptors and concomitant LCIS and DCIS using the
univariate analysis. Multivariate analysis revealed that only
concomitant LCIS and positive microscopic margins (R1-
status) remained independent predictors of IBTR.
IBTR rate was 4% after a median follow-up of
70.6 months in our study. The previously reported per-
centage of IBTR varies from 1.3% [25] to 8.5% [26].
Cabioglu et al. [25], explain their low number (IBTR rate
1.3%) with a decrease of IBTR in patients \50 years
within a specific time range in their observation period. In
our study we couldn’t find a lower incidence of IBTR in
younger patients. We therefore assume it to be the reason
for our higher IBTR rate.
Komoike et al. [26] reported patients treated before
1993 and described a 8.5% rate of IBTR within a median
follow-up period of 107 months. This is a considerable
longer median follow up compared to our study
Fig. 2 Overall survival of patients with tumour recurrence on any
site and without recurrence
Fig. 3 Overall survival in patients with distant metastases and all
other patients without distant disease
Fig. 1 Overall survival and the disease-free actuarial survival
Fig. 4 Overall survival of patients with IBTR and without IBTR
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(70.6 months). Another study [27] matching well the
median follow-up in Komoike’s work is reporting an IBTR
rate of 7.5%. They observed their patients until 1993 with a
follow up period of 103.2 month. Nottage et al. [28]
reported an IBTR rate of 6% after a follow-up of
Table 4 Results from
multivariate analysis
Variable P value
EIC 0.65
Resection margin 0.47
Tumor size 0.24
Tumor grading 0.47
R-status 0.001
Nodal-status 0.07
Multifocality 0.71
Concomitant DCIS 0.36
Concomitant LCIS 0.025
Positive ER-status 0.29
Positive PR-status 0.41
Table 5 Anatomic distribution of tumour recurrence
Recurrence Lymph
node
IBTR Distant
metastases
Lymph node 4 (1.2) 2 1 1
IBTR 14 (4.0) 1 11 2
Distant metastases 11 (3.1) 1 2 8
Total 27 (7.8) 4 14 11
Table 2 Analysed categorical
factors according to in-breast
tumour recurrence
Factors IBTR (n = 14) No IBTR (n = 332) Statistical
significance
N % N %
Histology
Lobular carcinoma 4 29 33 9.9 P \ 0.03
All other carcinomas 10 71 299 91.1
Grading
G1 and G2 8 57 331 99.7 P \ 0.0001
G3 6 43 1 0.3
Multifocality
Yes 4 29 25 7.5 P \ 0.02
No 10 71 307 92.5
Concomitant in situ carcinoma
DCIS 11 89 151 45.5 P \ 0.02
No DCIS 3 21 181 54.5
LCIS 4 29 17 5.1 P \ 0.0001
No LCIS 10 71 315 94.9
Receptor status
Estrogene Positive 8 57 266 80.1 P \ 0.02
Negative 6 43 66 19.9
Progesterone Positive 5 36 236 71.1 P \ 0.01
Negative 9 64 96 28.9
Margin status
R 0 11 89 310 93.4 P \ 0.04
R 1 3 21 22 6.6
Nodal status
N0 11 89 238 80.8 N.S.
N? 3 21 64 19.2
Table 3 Analysed non-parametric factors according to in-breast tumour recurrence
Factors IBTR No IBTR Significance
Median (Min; Max) Median (Min; Max)
Patient age at operation (years) 54 (41.5; 81.3) 59 (29.7; 92.8) N.S.
Tumour diameter (mm) 21.7 (20; 48) 16.0 (1; 73) N.S.
Resection margin (mm) 3.5 (\1; 8) 2.0 (\1; 25) N.S.
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130.8 months but they included patients only with free
margins in their study. Compared to our study, the higher
median follow up periods and the time period where the
patients were treated, may have caused the higher reported
IBTR rates in these three studies.
One publication is closer to our study setting and may
display a better comparison: The work of Elder et al. [29],
who also observed a similar period of time, found a IBTR
rate of 4.9% with a follow up time of 48 months.
Probably due to the limited number of patients in our
study, we could not demonstrate a statistically significant
association of IBTR with poorer overall survival, as has
been demonstrated by Fortin et al. [30].
One of the most important factors influencing the risk
for IBTR is the pathologic margin status after BCT [31].
Positive surgical margins seem to be relevant predictors for
systemic recurrence as well [32]. In our study we could
confirm that R1 resection was a statistically significant
predictor of IBTR. Of note, the resection margin in the
cases with IBTR was rather wider than in cases without
IBTR. This demonstrates, that adequate excision of the
tumor was accomplished and that the margins chosen, had
probably no impact on IBTR in our patients.
Although no clear guidelines concerning re-resection of
breast tissue have been determined, common practice aims
today at achieving microscopically free margins of more
than 1 mm [6].
More controversial than the R-status is the influence of
concomitant LCIS around the invasive tumor. As opposed
to Abner et al. [33] who have shown no significant dif-
ference between patients with concomitant LCIS in the
tumor bed and without, we could elucidate that presence of
LCIS has a significant influence on IBTR. Therefore, LCIS
when present with invasive breast cancer should carefully
be controlled during follow up. In addition, the impact of
other adjuvant modalities such as hormonal therapy in the
management of LCIS should be discussed as suggested by
Fisher et al. [16]. This theory is also confirmed by the work
of Jolly et al. [34], whose conclusion is, that LCIS may
have significant premalignant potential and progress to an
invasive IBTR at the site of index lesion.
Although several studies in the past have shown young
age as a significant risk factor for IBTR [11] we could only
show a trend towards this direction. We assume that the
smaller number of cases in the present study, compared to
Elkhuizen’s [11], might be a relevant reason for that.
In conclusion, with an observed IBTR rate of 4% our
results lay within the frequency range of IBTR in published
data. Moreover, we could implement that the impact of
concomitant LCIS and R1-margins are independent pre-
dictors for IBTR.
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